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Antipsychotic drugs have been used for more than 50
years in the management of psychotic symptomatology.
The dopamine-2 receptor (D2) antagonistic properties of
conventional antipsychotics, as probably the mechanism
of their action, formulated the dopamine hypothesis of
schizophrenia. This hypothesis is now revised, since
beyond the overactivation of dopaminergic systems in
mesolimbic dopamine pathway leading to the positive
symptoms, there is also evidence of hypodopaminergic
activity in the mesocortical dopamine pathway related to
the negative symptoms and cognitive impairment.
In the clinical practice, it has been observed that approxi-
mately one-fifth of patients do not respond to neuroleptic
drugs, even when there are high levels of D2 receptor
occupancy. Thus, with the progress in psychopharmacol-
ogy and the discovery that clozapine, an atypical antipsy-
chotic, binds to multiple receptors – other than D2
receptors – and the identification that serotoninergic and
other neurotransmitter systems are involved in the patho-
physiology and symptomatology of the disease, new com-
pounds have been isolated. More recently, the partial
agonistic activity at both D2 and serotonin receptors has
added a novel pharmacological treatment approach.
Atypical antipsychotic drugs have been developed with
multimodal mechanisms of action. These second genera-
tion antipsychotics have an increased therapeutic effect on
a broader spectrum of symptomatology, including the
positive and also the negative symptoms, combine effi-
cacy with good tolerability, and result in a better quality
of life and improved compliance. Switching to atypicals
can be associated with enhanced response rates. The use
of these compounds is now considered as first-line treat-
ment not only for patients with first episode psychosis,
but also in the long-term management of the disease.
Among them, important differences exist regarding their
potential to cause metabolic abnormalities and weight
gain.
Schizophrenia is a complex disease with high heterogene-
ity and multiformity in its clinical expression. The choice
of the pharmacological treatment should be based on the
existing guidelines, as well as on the balance of the risks
and benefits to the individual patient.
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